XClose

UCL School of Pharmacy

Home
Menu

Professor Peter Taylor

Professor of Microbiology

Tel: 020 7753 5867
peter.taylor@ucl.ac.uk

Responsibilities

  • Maplethorpe Fellowship Panel member
  • Experimental Bacteriology Steering Committee, Bloomsbury Research Institute member (UCL/LSHTM venture)

Research interests

  • Modification of bacterial phenotypes as an approach to the treatment of bacterial infections
  • Pathogenesis of Escherichia coli neonatal meningitis
  • Drug resistance in Staphylococcus aureus
  • Novel drugs for bacterial infections

Teaching interests

  • Treatment and control of infectious diseases
  • Antibiotics

Current collaborations and partnerships

  • Role of mucin in protection of the neonatal gastrointestinal tract: Gunnar Hansson, University of Gothenburg, Sweden; Brendan Wren, London School of Hygiene and Tropical Medicine, UK
  • Trafficking of opportunistic pathogens from gut to brain: Paul Luzio, University of Cambridge, UK; Eric Oswald, University of Toulouse, France
  • Abrogating β-lactam resistance in Staphylococus aureus: Vicente Micol, Miguel Hernández University, Elche, Spain; Simon Foster, University of Sheffield, UK; Tim Dafforn, University of Birmingham, UK; David Roper, University of Warwick, UK; Adriana Rosato, Methodist Hospital Research Institute, Houston, USA
  • Capsule depolymerases for anthrax therapy: Julia Vipond, PHE Porton Down, UK

Education

  • MIBiol, NESCOT, Ewell 1973
  • PhD in Medical Microbiology, Charing Cross Hospital Medical School 1975

Prof Peter Taylor

Appointments

  • Professor
    Pharmaceutics
    UCL School of Pharmacy

Joined UCL

1998-11-01

My major research interest involves novel approaches to the treatment of infectious disease; I am particularly interested in opportunities to develop therapeutics that suppress or abrogate the emergence of drug resistant variants by modification of the bacterial phenotype. One aspect involves the investigation of enzymes with therapeutic potential that resolve severe, systemic bacterial infections by stripping away the protective polysaccharide or polypeptide capsule; current activity in this area focuses on the capsule of Bacillus anthracis. Earlier work on the capsule of the neuropathogen Escherichia coli K1 has broadened into an investigation of the age dependency of neonatal bacterial sepsis and meningitis, with particular emphasis on initial colonization of the gastrointestinal tract. I also investigate a novel approach to the treatment of infections due to methicillin-resistant staphylococci (MRSA) based on modulation of beta-lactam resistance by catechin gallates derived from Japanese green tea. This focus on modification of bacterial phenotypes has also elicited activities on the impact of the modelled space environment on the fitness of pathogenic staphylococci.

I obtained my PhD in Medical Microbiology at Charing Cross Hospital Medical School in 1975. I was appointed to the School at the end of 1998 after a career that encompassed academia (Leeds University) and industry (Sandoz Research Institute in Vienna, Bayer Research Centres in Wuppertal and West Haven and the Ciba Geigy/Novartis Centre for Advanced Drug Delivery in Horsham). I was awarded a personal chair in 2005 and am currently Professor of Microbiology at UCL School of Pharmacy.